XML 83 R72.htm IDEA: XBRL DOCUMENT v3.23.3
SHAREHOLDERS' EQUITY (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Jul. 31, 2023
Mar. 31, 2023
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 17, 2021
May 20, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Proceeds from the issuance of common stock     $ 0 $ 7,020      
Unamortized issuance costs     $ 1,898   $ 3,849    
Warrants term             18 months
Warrants exercised (in shares)       400,000      
Common shares issued (in shares)       400,000      
Warrants outstanding       $ 0      
Zyla Life Sciences | Iroko | Warrant Agreements              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Exercise aggregate ownership percentage maximum threshold             49.00%
Zyla Life Sciences | Money market funds | Zyla Life Sciences              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Purchase price, number of shares outstanding, per share (in dollars per share)             $ 0.0016
Spectrum Pharmaceuticals, Inc.              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Issuance of common stock (in shares) 38,000,000            
At The Market Program              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Aggregate offering price           $ 25,000  
Stock offering, shares sold (in shares)     2,463,637        
Stock offering, purchase price (in dollars per share)     $ 3.02        
Stock offering, gross proceeds     $ 7,400        
Stock offering, net proceeds     7,000        
Additional Paid-In Capital              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Induced exchange of convertible notes, gross     28,300        
Convertible notes              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Unamortized issuance costs     1,600        
6.5% Convertible Senior Secured Notes due 2027 | Convertible notes              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Proceeds from the issuance of common stock   $ 10,500          
Induced exchange of convertible notes (in shares)   7,000,000          
Unamortized issuance costs     $ 1,600